Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Webcasts

Simplification of Continuous Tableting for Accelerated Product Development and Lifecycle Flexibility

June 12, 2024

Webinar Date/Time: Wednesday, July 10, 2024 - 11am EDT | 4pm GMT | 5pm CEST

Determination of Shelf-Life from Stability Data: From Replicates or from Averages?

June 11, 2024

A statistical analysis for determining an expiration date can be applied to replicates or their corresponding averages as suggested in industry guidelines.

Using Advanced Algorithms to Solve Formulation Challenges

June 09, 2024

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

The Intersection of Chemistry, Robotics, and AI in Drug Discovery (BIO 2024)

June 05, 2024

Lee Cronin, founder and CEO of Chemify, discusses the combination of digital chemistry, robotics, and AI in the drug discovery space.

Webcasts

Targeting Nitrosamine Precursors with Novel Active Material Science Scavenger Technologies

June 05, 2024

Webinar Date/Time: Thu, Jun 27, 2024 11:00 AM EDT

Webcasts

Insights from Commercial Implementation of Continuous Tableting: Successes and Challenges of a Partnership-Oriented Approach

June 04, 2024

Webinar Date/Time: Thursday, June 20, 2024 - 11am EDT | 4pm GMT | 5pm CEST

Webcasts

Risk-Based Development to Support Process Qualification for Spray-Dried Dispersions

June 03, 2024

Webinar Date/Time: Thu, Jun 20, 2024 11:00 AM EDT

Lilly Raises Investment in Indiana Site to $9 Billion to Expand API Manufacturing

May 30, 2024

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.

Sanofi Gets Priority Review Status for sBLA Seeking Approval of Sarclisa in Combination Therapy for Multiple Myeloma

May 30, 2024

FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.

Johnson & Johnson to Acquire Global Rights to Numab Therapeutics’ Bispecific Antibody for Atopic Dermatitis in $1.25 Billion Deal

May 30, 2024

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.